^
    23h
    Phase 1a/1b GTB-5550 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=175, Recruiting, Masonic Cancer Center, University of Minnesota
    New P1 trial • First-in-human
    |
    GTB-5550
    1d
    AAAV0505: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=6, Suspended, Columbia University | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • NKX019
    9d
    A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Virogin Biotech Ltd.
    New P2 trial
    |
    VG201
    15d
    GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Baylor College of Medicine
    New P1 trial
    |
    GPC3 (Glypican 3)
    |
    GPC3-CAR and IL15 plus IL21
    19d
    Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    26d
    Agni-01: Safety and Efficacy of OBX-115 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=208, Recruiting, Obsidian Therapeutics, Inc. | N=52 --> 208
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    cyclophosphamide • fludarabine IV • OBX-115
    28d
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Virogin Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Pan tumor
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    2ms
    Potent cytotoxic tumor-infiltrating lymphocytes can be generated from immune-excluded chondrosarcomas using regulatable membrane-bound IL15. (PubMed, Cancer Immunol Res)
    Here, we report the successful generation and expansion of TIL engineered with regulatable, membrane-bound IL15 (cytoTIL15™ cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2...Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.
    Journal • Tumor mutational burden • Tumor-infiltrating lymphocyte • IO biomarker
    |
    TMB (Tumor Mutational Burden) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
    |
    TMB-L
    |
    OBX-115
    3ms
    CALiPSO-1: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Century Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=48 --> 6
    Enrollment closed • Enrollment change
    |
    CNTY-101
    4ms
    IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Seattle Children's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
    P1, N=28, Terminated, Century Therapeutics, Inc. | Trial completion date: Aug 2027 --> Jul 2025 | Active, not recruiting --> Terminated; Strategic decision
    Trial completion date • Trial termination
    |
    CD19 positive
    |
    CNTY-101